Consolidated Laboratories, Inc. v. Shandon Scientific Company, Ltd.

413 F.2d 208, 1969 U.S. App. LEXIS 11651
CourtCourt of Appeals for the Seventh Circuit
DecidedJuly 2, 1969
Docket17326_1
StatusPublished
Cited by1 cases

This text of 413 F.2d 208 (Consolidated Laboratories, Inc. v. Shandon Scientific Company, Ltd.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Consolidated Laboratories, Inc. v. Shandon Scientific Company, Ltd., 413 F.2d 208, 1969 U.S. App. LEXIS 11651 (7th Cir. 1969).

Opinion

413 F.2d 208

CONSOLIDATED LABORATORIES, INC., a corporation, Plaintiff-Appellant,
v.
SHANDON SCIENTIFIC COMPANY, Ltd., a corporation, Shandon
Scientific Company, Inc., a corporation, Shandon Scientific
Industries, Ltd., a corporation, Ernest R. Shandon, and
George D. Welch, Defendants-Appellees.

No. 17326.

United States Court of Appeals Seventh Circuit.

July 2, 1969.

Patrick W. O'Brien, George Bobrinskoy, Jr., Chicago, Ill., for appellant.

Laurens G. Hastings, David P. List, Henry Mason, III, Chicago, Ill., for appellee.

Before HASTINGS, Senior Circuit Judge, and KILEY and SWYGERT, Circuit judges.

HASTINGS, Senior Circuit Judge.

Plaintiff, Consolidated Laboratories, Inc. (Consolidated), appeals from a summary judgment of dismissal entered by the district court for the defendants, Shandon Scientific Company, Ltd., Shandon Scientific Industries, Ltd. (Shandon of London),1 Shandon Scientific Company, Inc. (Shandon of Pennsylvania), corporations, and Ernest R. Shandon, and George D. Welch. We shall summarize the facts relevant to this appeal.2

Consolidated instituted this diversity action charging that Shandon of London breached its contract with Consolidated and that Shandon of Pennsylvania and its president, George Welch, and Ernest Shandon unlawfully and maliciously induced such breach of contract. Consolidated sought an injunction and damages.

The record reveals that Shandon of London is an English manufacturer of scientific products for biological and biochemical laboratories. Beginning in the final quarter of 1950, Consolidated became the sole distributor for Shandon scientific equipment in the United States. After negotiations, Consolidated and Shandon of London formalized this relationship by executing a written contract on May 15, 1963, which provided that Consolidated would have 'exclusive rights to market' certain Shandon products in the United States and in specified Territories for a period of five years.

It is evident there was economic dissatisfaction with the business relationship established under the 1963 agreement. The precise reasons for the dissatisfaction appear to be in dispute.

An affidavit filed by Ernest R. Shandon states that he met with Dr. George H. Scherr, Vice-President and Chairman of the Board of Directors of Consolidated, on June 28, 1965, at Consolidated's Illinois office. Shandon states that during this meeting he discussed with Scherr the possibility of canceling their 1963 contract due to Consolidated's failure to perform in accordance with the terms of that contract. The discussion allegedly focused on Consolidated's failure to meet the terms of payment,3 failure to adequately promote and advertise Shandon's products and failure to maintain an adequate rate of growth in sales.

By affidavit, Dr. Scherr states that he had occasion to meet with Ernest Shandon on May 12, 1964, and on June 28, 1965. At the May, 1964 conference, discussion concerned resolving 'three significant problems' which had arisen under the 1963 agreement: restyling Shandon products to suit the demands of the American market, reducing the time lag between Consolidated orders and delivery by Shandon of London and improving the allocation of credit burden between the parties. At the June, 1965 meeting, affiant states that Ernest Shandon voiced dissatifaction at the rate of growth in Shandon sales but expressly stated that he could not 'find fault with the efforts and performance of Consolidated in promoting the sale of Shandon Products * * *', and that there was no threat of canceling the 1963 agreement.

The record further reveals that on September 23, 1965, a meeting took place in London between Dr. Scherr and Shandon of London's board of directors. As a result of this conference, the parties mutually agreed to terminate the 1963 contract and did so by a written memorandum which in relevant part reads:

'Memorandum that it has been agreed between the undersigned Shandon Scientific Co., Ltd., and Consolidated Laboratories Inc., as follows:

(1) The Memorandum of Agreement made between us dated 1st May 1963 shall be and is hereby terminated by mutual consent in consideration of the exchange of the attached letter of intent dated the 27th September, 1965.

(2) Each party hereby agrees and acknowledges that it has no outstanding claim against the other except in respect of goods supplied.'

The 'letter of intent' referred to by the parties in the memorandum of cancellation redefined the Consolidated-Shandon of London contractual relationship and in relevant part reads:

'We hereby confirm that from today's date, until the appointment of a new main distributor in the United States, we shall continue to supply you with those Shandon products scheduled in the Agreement dated the 1st May, 1963, at current prices directly from London.

'Payment terms to be as follows:-- 90 days documents against por aval acceptance by a U.S.A. bank.

'We also confirm that we will ensure that on appointment of a new main distributor you will be assured a main dealership for Shandon products at most favoured terms under an agreement to be negotiated between yourselves and the new main distributor. It is intended that the latter will only supply a small number of major dealers, of which you would be one, and will not deal directly with users.

'Consolidated Laboratories have the prerogative to sell back to Shandon Scientific Co. Ltd. those stocks which they do not require at the date of appointment of the new main distributor. Consolidated Laboratories intentions in this matter will be communicated by them to Shandon Scientific Co. Ltd. so that the physical disposal can be organised. The stocks will be sold to Shandons at cost price plus duty.'

Under this new relationship, the parties contemplated that Shandon of London would appoint a new main distributor for the United States and that until such appointment Shandon of London would continue to sell products to Consolidated at current prices under payment terms of '90 days documents against por aval acceptance by a U.S.A. bank.' The parties further agreed that the new main distributor would sell only to a small number of major dealers and would not sell directly to the public. The agreement expressly assured Consolidated of a main dealership at 'most favoured terms.'

It is undisputed that Shandon of London did not appoint a new main distributor, but rather in May, 1966 it organized Shandon of Pennsylvania, advertised as an American subsidiary of Shandon of London, to 'sell and distribute, at wholesale and retail', Shandon products. Ernest Shandon is principal shareholder in Shandon of Pennsylvania while George Welch, a 10 per cent shareholder, serves as its president. Shortly after incorporation, the Pennsylvania Company solicited retail sales for Shandon products by advertising in various scientific journals and by direct mailings.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lakeview Collection Inc. v. Bank of America, N.A.
942 F. Supp. 2d 830 (N.D. Illinois, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
413 F.2d 208, 1969 U.S. App. LEXIS 11651, Counsel Stack Legal Research, https://law.counselstack.com/opinion/consolidated-laboratories-inc-v-shandon-scientific-company-ltd-ca7-1969.